Over the course of a decade, out-of-pocket costs for multiple sclerosis drugs rose more than sevenfold for Medicare Part D beneficiaries, according to a JAMA Neurology study published today by researchers at the University ...
Aug 26, 2019
0
4
Drug companies are still raising prices for brand-name prescription medicines, just not as often or by as much as they used to, according to an Associated Press analysis.
Aug 19, 2019
0
0
Greater brand-brand competition alone will likely not lower list prices of brand-name drugs in the US, according to a study published July 30 in the open-access journal PLOS Medicine by Ameet Sarpatwari of Brigham and Women's ...
Jul 30, 2019
0
4
(HealthDay)—Its extremely high price tag means that a lifesaving medication to treat young children with spinal muscular atrophy is simply too expensive for most families.
Jul 30, 2019
0
1
An initiative to improve access to high-cost hepatitis C treatments in poorer countries has resulted in more people being treated for the disease.
Jul 29, 2019
0
3
Two senior senators—a Republican and a Democrat—unveiled compromise legislation Tuesday to reduce prescription drug costs for millions of Medicare recipients, while saving money for federal and state health care programs ...
Jul 23, 2019
0
0
An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A. Burns School of Medicine (JABSOM) researcher at the University ...
Jul 23, 2019
0
2
Most consumers haven't shopped around for standard medical procedures such as a knee replacement, but reference pricing could open that possibility for many services and lower health care costs at the same time.
Jul 15, 2019
0
2
Efforts to control health care costs in the United States often focus on the listed prescription drug prices, but a perspective published by the Journal of the American Medical Association suggests that unregulated pharmacy ...
Jun 21, 2019
0
1
Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.
Jun 17, 2019
0
0
